Al-Akwaa Ahmad M, Siddiqui Neelam, Al-Mofleh Ibrahim A
Gastroenterology Division, Neelam Siddiqui Oncology Division, Department of Medicine, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
World J Gastroenterol. 2004 Jan;10(1):5-11. doi: 10.3748/wjg.v10.i1.5.
The purpose of this review is to describe the various aspects of primary gastric lymphoma and the treatment options currently available.
After a systematic search of Pubmed, Medscape and MDconsult, we reviewed and retrieved literature regarding gastric lymphoma.
Primary gastric lymphoma is rare however, the incidence of this malignancy is increasing. Chronic gastritis secondary to Helicobacter pylori (H pylori) infection has been considered a major predisposing factor for MALT lymphoma. Immune histochemical marker studies and molecular biology utilizing polymerase chain reaction have facilitated appropriate diagnosis and abolished the need for diagnostic surgical resection. Advances in imaging techniques including Magnetic Resonance Imaging (MRI) and Endoscopic Ultrasonography (EUS) have helped evaluation of tumor extension and invasion. The clinical course and prognosis of this disease is dependent on histopathological sub-type and stage at the time of diagnosis. Controversy remains regarding the best treatment for early stages of this disease. Chemotherapy, surgery and combination have been studied and shared almost comparable results with survival rate of 70-90%. However, chemotherapy possesses the advantage of preserving gastric anatomy. Radiotherapy alone has been tried and showed good results. Stage IIIE, IVE disease treatment is solely by chemotherapy and surgical resection has been a remote consideration.
We conclude that methods of diagnosis and staging of the primary gastric lymphoma have dramatically improved. The modalities of treatment are many and probably chemotherapy is superior because of high success rate, preservation of stomach and tolerable complications.
本综述旨在描述原发性胃淋巴瘤的各个方面以及目前可用的治疗选择。
在对PubMed、Medscape和MDconsult进行系统检索后,我们查阅并检索了有关胃淋巴瘤的文献。
原发性胃淋巴瘤较为罕见,但其发病率正在上升。幽门螺杆菌(H pylori)感染继发的慢性胃炎被认为是黏膜相关淋巴组织(MALT)淋巴瘤的主要诱发因素。免疫组织化学标志物研究以及利用聚合酶链反应的分子生物学技术有助于进行准确诊断,不再需要进行诊断性手术切除。包括磁共振成像(MRI)和内镜超声检查(EUS)在内的成像技术的进步有助于评估肿瘤的扩展和侵犯情况。该疾病的临床病程和预后取决于诊断时的组织病理学亚型和分期。对于该疾病早期的最佳治疗方法仍存在争议。已经对化疗、手术及联合治疗进行了研究,其结果相近,生存率为70%至90%。然而,化疗具有保留胃解剖结构的优势。单独放疗也已尝试并显示出良好效果。IIIE期、IVE期疾病仅通过化疗进行治疗,手术切除已很少被考虑。
我们得出结论,原发性胃淋巴瘤的诊断和分期方法有了显著改进。治疗方式多种多样,化疗可能更具优势,因为其成功率高、能保留胃且并发症可耐受。